Search

Your search keyword '"Ghelardi A"' showing total 1,052 results

Search Constraints

Start Over You searched for: Author "Ghelardi A" Remove constraint Author: "Ghelardi A"
1,052 results on '"Ghelardi A"'

Search Results

1. Trend of HPV 16/18 Genotypes in Cervical Intraepithelial Neoplasia Grade 3: Data for 2007–2018

2. Quantifying Quality: The Impact of Measures of School Quality on Children's Academic Achievement across Diverse Societies

3. Effectiveness of a new commercial ocular spray containing Biosecur in reducing conjunctival microbial flora as surgical prophylaxis in patients undergoing cataract surgery

4. Measuring preparedness to infectious diseases among people exposed to climate disasters in Cabo Delgado, Mozambique: a cross-sectional study

6. Measuring preparedness to infectious diseases among people exposed to climate disasters in Cabo Delgado, Mozambique: a cross-sectional study

8. Cultivating complexity: Advancements in establishing in vitro models for the mucus‐adhering gut microbiota

10. Hospital distribution, seasonality, time trends and antifungal susceptibility profiles of all Aspergillus species isolated from clinical samples from 2015 to 2022 in a tertiary care hospital

11. Anti-staphylococcal activity of a polyphenol-rich citrus extract: synergy with β-lactams and low proficiency to induce resistance

12. Implications of hormonal carcinogenesis for transgender and gender-diverse people undergoing gender-affirming hormone therapy: an up-to-date review

13. Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: The phase 2 non-randomized SUTNET clinical trial

17. Examining Relations between Performance on Non-Verbal Executive Function and Verbal Self-Regulation Tasks in Demographically-Diverse Populations

18. Treatment of patients with BRAFV600E-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset

20. Type 2 diabetes mellitus pharmacological remission with dapagliflozin plus oral semaglutide

21. Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma—a retrospective, international, multicentric AGEO study

23. Type 2 diabetes mellitus pharmacological remission with dapagliflozin plus oral semaglutide

24. Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV

25. Mytomicin-C, Metronomic Capecitabine, and Bevacizumab in Patients With Unresectable or Relapsed Pseudomyxoma Peritonei of Appendiceal Origin

26. Anti-Staphylococcal Biofilm Effects of a Liposome-Based Formulation Containing Citrus Polyphenols

27. Synthetic Seed Production and Slow Growth Storage of In Vitro Cultured Plants of Iris pallida Lam.

28. Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors

29. Antimicrobial Activity of Xibornol and a Xibornol-Based Formulation Against Gram-Positive Pathogens of the Respiratory Tract

30. Predictive Impact of RNF43 Mutations in Patients With Proficient Mismatch Repair/Microsatellite Stable BRAFV600E-Mutated Metastatic Colorectal Cancer Treated With Target Therapy or Chemotherapy

31. FOLFOXIRI/bevacizumab (bev) versus doublets/bev as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated (mut) metastatic colorectal cancer (mCRC): An individual patient data-based pooled analysis of randomized trials.

32. Animal and In Vitro Models as Powerful Tools to Decipher the Effects of Enteric Pathogens on the Human Gut Microbiota

34. Dapagliflozin acutely improves kidney function in type 2 diabetes mellitus. The PRECARE study

38. Comparison of different microbiological procedures for the diagnosis of Pneumocystis jirovecii pneumonia on bronchoalveolar-lavage fluid

39. Cultivating complexity: Advancements in establishing in vitro models for the mucus‐adhering gut microbiota.

40. Quantifying quality: The impact of measures of school quality on children's academic achievement across diverse societies.

42. Genomic Diversity and Virulence Genes Characterization of Bacillus cereus sensu lato Isolated from Processing Equipment of an Algerian Dairy Plant

43. Supplementary Figure S5 from Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer

44. Supplementary Video S1 from Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer

45. Supplementary Tables S1-S19 from Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer

46. Supplementary Methods S1 from Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer

47. The Prognostic Nutritional Index in patients with microsatellite instability-high metastatic gastric or gastroesophageal cancers receiving immune checkpoint inhibitors

48. Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer

50. TUMOuR IMMUNE MICROENVIRONMENT (TIME) IN BPV1-POSITIVE EQUINE SARCOIDS

Catalog

Books, media, physical & digital resources